Jiyan Liu

4.5k total citations · 1 hit paper
160 papers, 2.8k citations indexed

About

Jiyan Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jiyan Liu has authored 160 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Jiyan Liu's work include Cancer Immunotherapy and Biomarkers (25 papers), Colorectal Cancer Treatments and Studies (18 papers) and Gastric Cancer Management and Outcomes (17 papers). Jiyan Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Colorectal Cancer Treatments and Studies (18 papers) and Gastric Cancer Management and Outcomes (17 papers). Jiyan Liu collaborates with scholars based in China, United States and United Kingdom. Jiyan Liu's co-authors include Yuwen Zhou, Xuelei Ma, Tingting Jiang, Yajuan Zhu, Zhenyu Ding, Ji‐Cheng Li, Liliang Wei, Xiuyun Yang, Liansha Tang and Ye Chen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jiyan Liu

152 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

2020 192 citations Xinan Sheng, Jiyan Liu et al. profile →

Peers

Jiyan Liu

ONCOL

PRM

SURGE

IMMUN

Xicheng Wang China

Sarah Wheeler United States

Daniele Morelli Italy

Freda Passam Australia

Jeong Heo South Korea

Pei Hui United States

Xiuwen Wang China

F Zintl Germany

Shin Mineishi United States

Hans Schlößer Germany

Xicheng Wang China

Jiyan Liu

1.2k ×1.0

ONCOL

904 ×1.0

528 ×1.0

PRM

407 ×0.8

SURGE

531 ×1.3

IMMUN

Citations per year, relative to Jiyan Liu Jiyan Liu (= 1×) peers Xicheng Wang

Countries citing papers authored by Jiyan Liu

Since Specialization

Citations

This map shows the geographic impact of Jiyan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiyan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiyan Liu more than expected).

Fields of papers citing papers by Jiyan Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiyan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiyan Liu. The network helps show where Jiyan Liu may publish in the future.

Co-authorship network of co-authors of Jiyan Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiyan Liu. A scholar is included among the top collaborators of Jiyan Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiyan Liu. Jiyan Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Ruizhi, et al.. (2025). Causal relationship between immune cell signatures and colorectal cancer: a bi-directional, two-sample mendelian randomization study. BMC Cancer. 25(1). 387–387. 2 indexed citations

Zhou, Yuwen, Qian Xu, Jialing Wang, et al.. (2024). Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. 17(3). 667–674. 1 indexed citations

Yu, Yongxin, et al.. (2024). The roles of cancer stem cells and therapeutic implications in melanoma. Frontiers in Immunology. 15. 1486680–1486680. 5 indexed citations

Zhu, Yuchun, Jingjing Wang, Li Dong, et al.. (2024). Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. Nature Communications. 15(1). 10371–10371. 5 indexed citations

Zeng, Hao, Xingming Zhang, Jiayu Liang, et al.. (2024). Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).. Journal of Clinical Oncology. 42(16_suppl). 4523–4523. 1 indexed citations

Chen, Junru, Chenhao Xu, Qiang Wei, et al.. (2024). Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.. Journal of Clinical Oncology. 42(16_suppl). TPS4625–TPS4625. 1 indexed citations

Meng, Wenjun, et al.. (2024). Innovative Nanomedicine Delivery: Targeting Tumor Microenvironment to Defeat Drug Resistance. Pharmaceutics. 16(12). 1549–1549. 14 indexed citations

Zhu, Yajuan, Jiaxiang Wang, Xiaoli Mu, et al.. (2023). Personalised neoantigen‐based therapy in colorectal cancer. Clinical and Translational Medicine. 13(11). e1461–e1461. 12 indexed citations

Zhu, Yajuan, et al.. (2023). Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis. European journal of medical research. 28(1). 422–422. 3 indexed citations

10.

Li, Xi, Lei Yi, Jiyan Liu, et al.. (2023). Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies. Discover Oncology. 14(1). 146–146. 3 indexed citations

11.

Si, Lu, Zhengyun Zou, Weizhen Zhang, et al.. (2023). Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9510–9510. 5 indexed citations

12.

He, He, et al.. (2020). <p>Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database</p>. Pharmacogenomics and Personalized Medicine. Volume 13. 365–373. 6 indexed citations

13.

Gao, Doudou, Sisi Luo, Yuhong Zhang, et al.. (2018). Mn3O4/carbon nanotubes nanocomposites as improved anode materials for lithium-ion batteries. Journal of Solid State Electrochemistry. 22(11). 3409–3417. 14 indexed citations

14.

Zhang, Weili, Shulun Ai, Jiyan Liu, et al.. (2018). Photothermally Enhanced Chemotherapy Delivered by Graphene Oxide-Based Multiresponsive Nanogels. ACS Applied Bio Materials. 2(1). 330–338. 6 indexed citations

15.

Zhang, Weili, Shulun Ai, Yuhong Zhang, et al.. (2018). Hybridization of graphene oxide into nanogels to acquire higher photothermal effects for therapeutic delivery. Nanotechnology. 30(11). 115701–115701. 18 indexed citations

16.

Ding, Jing, Yueting Zhu, Lie Yang, et al.. (2018). 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. Carcinogenesis. 39(3). 493–502. 5 indexed citations

17.

Zhang, Xingming, Pengfei Shen, Jin Yao, et al.. (2018). Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma. Medicine. 97(31). e11565–e11565.

18.

Xiao, Biao, Jingnan Song, Bing Guo, et al.. (2017). Improved photocurrent and efficiency of non-fullerene organic solar cells despite higher charge recombination. Journal of Materials Chemistry A. 6(3). 957–962. 14 indexed citations

19.

Wu, Jing, Ke Cheng, Yang Du, et al.. (2015). Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy. Clinical Genitourinary Cancer. 14(1). e135–e137. 4 indexed citations

20.

Peng, Xingchen, Yang Li, Liping Yang, et al.. (2008). Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant. Journal of Experimental & Clinical Cancer Research. 27(1). 46–46. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact